Valuation : Tsubota Laboratory Incorporated

Market Cap 7.48B 46.7M 40.33M 37.79M 34.54M 64.94M 4.46B 65.25M 445M 175M 2.26B 175M 172M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 6.58B 41.07M 35.48M 33.24M 30.38M 57.12M 3.92B 57.39M 391M 154M 1.98B 154M 151M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
Aug. 11 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
Jun. 16 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
May. 31 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
May. 31 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
May. 15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
May. 15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
Feb. 13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
Feb. 13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
25-05-11 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
25-02-17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
24-11-20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
22-12-18 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
22-09-19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
Manager TitleAgeSince
President 71 2019-01-31
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 2024-12-31
Director TitleAgeSince
Director/Board Member 71 2019-01-31
Director/Board Member 70 2020-05-31
Director/Board Member 55 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 46.96M
-0.78%-0.34%+1.99%+23.35% 51.14B
-6.00%-1.82%+446.48%+527.28% 47.4B
-0.24%+2.23%+38.64%+19.52% 43.19B
-1.55%-0.66%+22.19%+84.83% 42.35B
-0.31%-1.75%+17.23%+52.37% 33.23B
-1.79%-1.96%+26.86%+131.18% 17.07B
-0.58%-2.71% - - 16.38B
-0.88%-0.63%+11.05%+29.54% 14.76B
-1.66%+0.02%+79.05%+45.47% 14.15B
Average -0.73%+0.70%+80.44%+114.19% 31.07B
Weighted average by Cap. -0.63%+1.12%+99.46%+135.52%

Financials

2025 2026
Net sales 1.36B 8.47M 7.32M 6.86M 6.27M 11.78M 808M 11.84M 80.67M 31.7M 409M 31.83M 31.14M 200M 1.25M 1.08M 1.01M 924K 1.74M 119M 1.74M 11.89M 4.67M 60.3M 4.69M 4.59M
Net income 205M 1.28M 1.11M 1.04M 947K 1.78M 122M 1.79M 12.19M 4.79M 61.8M 4.81M 4.7M -761M -4.75M -4.1M -3.84M -3.51M -6.61M -453M -6.64M -45.24M -17.78M -229M -17.85M -17.46M
Net Debt -1.45B -9.04M -7.81M -7.32M -6.69M -12.57M -862M -12.63M -86.08M -33.83M -437M -33.97M -33.23M -901M -5.62M -4.86M -4.55M -4.16M -7.82M -537M -7.86M -53.56M -21.05M -272M -21.14M -20.68M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-